However, the negative TdT and expression of BCL6 in a subset of malignant cells raise the possibility of a high grade B-cell lymphoma with MYC and BCL2 rearrangements [9] or a lymphoblastic transformation of follicular lymphoma [10], although there is no clinical evidence to support these diagnoses. This evidence concerns the gene BCL6 and B-cell non-Hodgkin lymphoma.